Oricell Therapeutics
Funding reported, Pre-Seed, last update 4 months ago
Pharma biotech · Headquarters China
Everything we hold on Oricell Therapeutics, newest first. Every line links to the filing or report it came from.
This profile is thin because we hold one source document on Oricell Therapeutics so far, not because nothing else has happened there. We only publish what we have read on a primary source and can link to. So a profile fills up as filings and reports come in, and we never seed it from an estimate. We keep profiles at this stage out of our sitemap and mark them noindex until they carry enough to be worth a search result of their own.
- 2026-04-10Headcount Not Stated Growing and expanding
China-based CAR-T company Oricell raises $40M more as it looks to go public
Oricell Therapeutics, a China-based developer of CAR-T therapies for solid tumors, raised $40M in pre-IPO financing ahead of a public listing, funding that typically expands research and clinical headcount. The announcement names no specific roles.
The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker